ADC Therapeutics books $21m Zynlonta sales and projects funding into 2029 after October financing
Third-quarter sales of the lymphoma drug reached $21.0m, while a share placement and renegotiated debt and royalty terms underpin the balance sheet.
ADC Therapeutics said on 9 November that Zynlonta generated $21.0m in net product revenue in the quarter ended 30 September. The company held $189.2m in cash at the end of the period.
The balance sheet was reshaped in October. ADC raised $86.6m through a private investment in public equity (PIPE) and amended its royalty and loan agreements. Together, the company says, these steps mean its cash should last into 2029. The summary provided does not give the terms of the amended agreements, so their effect on future payment obligations is not detailed here.
Japan is the main regulatory development. ADC's partner Tanabe Pharma has submitted a marketing authorisation application to the country's health ministry, the MHLW, for Zynlonta in relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after at least two systemic therapies. Tanabe has also sublicensed the product to Nippon Shinyaku. The material does not say when a decision is expected.
In December, ADC will have five oral presentations on Zynlonta at the American Society of Hematology (ASH) annual meeting. The company has not disclosed what data will be shown in this update.
Why it matters
- The October financing and amended debt and royalty terms put the company's stated funding horizon at 2029, reducing near-term balance-sheet pressure, though the terms of the amendments are not detailed.
- Zynlonta's $21.0m quarterly sales set the commercial baseline against which any Japanese launch or label expansion will be measured.
- The Japanese filing and the Tanabe-to-Nippon Shinyaku sublicence mean commercial responsibility in that market involves more than one company, which is relevant to anyone mapping partnerships.
- The five ASH oral presentations in December are the next scheduled opportunity for new Zynlonta data.
Company's press release (SEC filing): ADC Therapeutics SA ↗
Written by CompePharma's editorial system from the company's filing; claims are the company's. AI-assisted; check the source before acting. Not investment advice.
BeyondSpring wins FDA Fast Track for plinabulin-docetaxel in post-immunotherapy NSCLC as cash dwindles to $0.6M
Calidi cuts costs and restructures as Q3 loss reaches $3.6M ahead of CLD-401 IND
Beyond Air reports record $2.3M quarterly revenue as FDA reviews second-generation LungFit PH
DataMEDS AI Q3 revenue up 50% to $2.7M on GLP-1 dispensing
Curis reports Q3 loss of $8.1m as emavusertib trials enrol; cash runway reaches only early 2027
